Parkinson`s disease News
-
NIH study finds two pesticides associated with Parkinson`s disease
New research shows a link between use of two pesticides, rotenone and paraquat, and Parkinson's disease. People who used either pesticide developed Parkinson's disease approximately 2.5 times more often than non-users. The study was a collaborative effort conducted by researchers at the National Institute of Environmental Health Sciences (NIEHS), which is part of the National Institutes of ...
-
NIH study finds two pesticides associated with Parkinson`s disease
New research shows a link between use of two pesticides, rotenone and paraquat, and Parkinson's disease. People who used either pesticide developed Parkinson's disease approximately 2.5 times more often than non-users. The study was a collaborative effort conducted by researchers at the National Institute of Environmental Health Sciences (NIEHS), which is part of the National Institutes of ...
-
Population diagnostics awarded two federal grants to support its autism and parkinson’s disease programs
Grant Awards – November 2, 2010 – Population Diagnostics was awarded two federal grants totaling $489,000 under a provision of the Patient Protection and Affordable Care Act enacted in 2010. The grant applications, which were reviewed and approved by the Department of Health and Human Services (HHS), are entitled: "Development of an Autism Early Detection Genetic Test" ...
-
New Parkinson`s Disease Genes Discovered by the Parkinson`s Institute and Clinical Center and Population Diagnostics, Inc.
Collaborative Effort to Further Validate Genetic Variants SUNNYVALE, Calif. and MELVILLE, N.Y., Nov. 20, 2013 /PRNewswire-USNewswire/ -- The Parkinson's Institute and Clinical Center announced today that they, in partnership with Population Diagnostics, Inc., have discovered a number of new genes relevant to the cause of Parkinson's disease. The innovative approach used for this study focuses ...
-
Newronika Raises an 8.4M EUR Series-A Round
Newronika, a spin-off of world-class neurological research centers Policlinico of Milan and University of Milan, has raised an 8.4 million Euros Series-A round. The investment was led by French venture capital fund Omnes together with existing investors Innogest Capital and Indaco Venture Partners SGR ("Indaco SGR") on behalf of Indaco Ventures I and Atlante Ventures funds. F3F and an undisclosed ...
-
Lauren Sciences LLC awarded second Michael J. Fox Foundation grant to further develop V-Smart Therapeutic for Parkinson`s disease
New York, N.Y., June 25, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company continuing development of its novel V-Smart™ platform technology, announced today the award of a second grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF). The company recently completed the first stage of developing V-Smart™-based therapeutics for the treatment of ...
-
Link between pesticides and Parkinson`s disease
A study conducted in the United States, published this week, adds to the body of research linking pesticides and Parkinson's. Researchers compared people with Parkinson's to family members and found that those with Parkinson's had had greater exposure to pesticides. Kieran Breen, Director of Research at the Parkinson’s Disease Society (PDS) said: 'The association between pesticides and ...
-
NeuroOne Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the publication of the 2022 Annual Letter to Shareholders published in the Company's Proxy Statement for its Annual Meeting of Stockholders that occurred on ...
-
Esteve Launches INBRIJA in Germany
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.(1) Under ...
-
Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA in Latin America
Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have entered into distribution and supply agreements to commercialize INBRIJA in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase ...
-
MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the successful completion of its first clinical trial of anle138b (NCT04208152) in healthy volunteers. The Company’s lead candidate, which was administered in doses of up to 300 mg daily, demonstrated excellent safety and ...
By MODAG GmbH
-
People with Parkinson’s Disease may have double the risk for Melanoma, a dangerous skin cancer
An analysis of several studies shows that people with Parkinson’s disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases. The research is published in the June 7, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. Parkinson’s disease is a brain disorder ...
-
People with Parkinson’s disease may have double the risk for melanoma, a dangerous skin cancer
An analysis of several studies shows that people with Parkinson’s disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases. The research is published in the June 7, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. Parkinson’s disease is a brain disorder ...
-
VeriSIM Life Announces Acquisition of Molomics Biotech
VeriSIM Life (VeriSIM), the leading Artificial Intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced the acquisition of Molomics Biotech, a privately-held drug discovery company that leverages proprietary AI technology to design more efficacious and safer therapeutics to achieve higher successes in clinical trials. Founded in 2015 in ...
By VeriSIM Life
-
Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson`s patients
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients. The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, ...
By Renishaw plc
-
Population Bio Recognizes World Rare Disease Day 2017 with a Commitment to Provide New Insights into Rare Diseases
Pioneering technology platform rapidly uncovers the genetic causes of unsolved diseases and redefines the understanding of rare and complex genetic diseases. Melville, NY, (February 28, 2017) Population Bio (PB) – a global leader in gene discovery announced, in support of World Rare Disease Day, its continued investment in its CNV Beacon® gene discovery platform which delivers new ...
-
Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson’s disease. The trial, AKST4290-211 (TEAL), is funded in part by The Michael J. Fox Foundation for ...
-
Levodopa Cyclops in Dutch magazine ‘Tijdschrift voor Neurologie en Neurochirurgie (TNN)’
OFF episodes are an unmet medical need with a great impact on the quality of life of Parkinson’s disease patients. Oral levodopa does not prevent the occurrence of OFF episodes, nor enables their fast resolve, mainly because of a highly variable and unreliable absorption through this route of administration. The pulmonary administration of levodopa results in faster and more reliable ...
By Pureims B.V.
-
Revolutionary non-invasive technology supporting early diagnosis of Parkinson’s disease showcased at MEDICA 2021
Manus Neurodynamica Limited (“Manus”), who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to launch their revolutionary non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment. The NeuroMotor Pen (NMP) is a unique, ...
-
NDI Launches Deep Brain Innovations, LLC
NDI Medical, LLC, a venture and commercialization firm that funds and develops innovative neurodevice technologies, has launched its next portfolio company, Deep Brain Innovations, LLC (DBI). DBI will commercialize its groundbreaking technology that is designed to optimize deep brain stimulation (DBS) therapy for patients with Parkinson’s disease. Currently available DBS therapy is ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you